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Abstract 
The synthesis of cocrystals is presented as an alternative to improve the properties of active 
pharmaceutical ingredients, especially those related to solubility and dissolution rate. In this work the 
dissolution rate of ciprofloxacin, a zwitterionic fluoroquinolone antibiotic, has been compared to its 
cocrystal with resorcinol. To this end, dissolution rate has been determined at several biorelevant pH 
values, and also in two simulated gastrointestinal fluids (FeSSIF and FaSSIF). Results show that both, 
ciprofloxacin and the cocrystal, dissolve more slowly as pH increases (from 2.0 to 7.4), as ionization degree 
of ciprofloxacin decreases. In addition, dissolution is not enhanced by the components of the 
gastrointestinal fluids.  
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Introduction 
The dissolution rate plays an important role in drugs with limited solubility. In fact, for drugs with very 
poor aqueous solubility, the rate at which they dissolve is often the slowest step, and it exerts a rate-
limiting effect on drug bioavailability. Currently about 60 % of the drugs coming from synthesis are poorly 
soluble and hence have a low oral bioavailability [1]. Diverse strategies have been developed to improve 
solubility, dissolution rate and subsequently the bioavailability of these drugs. These include formation of 
salts, inclusion complexes with cyclodextrines, amorphization, formulation of solid dispersions with 
hydrophilic polymers, changing the crystal form (polymorphs, hydrates, etc.) [2-5]. A promising strategy is 
the crystallisation of the drug with a suitable coformer to obtain a cocrystal, which may have different 
physical properties compared to the drug, such as melting point, moisture sorption, compressibility, 
solubility, and dissolution rate, without altering the pharmacological effect of the drug candidate [4-7]. 
A cocrystal can be defined as a stoichiometric multi-component system connected by non-covalent 
interactions where all the components present are solid under ambient conditions [5]. A pharmaceutical 
cocrystal is composed of an active pharmaceutical ingredient (API) and a suitable and pharmaceutically 
C. Ràfols et al.  ADMET & DMPK 6(1) (2018) 61-70 
62  
accepted molecule called a coformer. Cocrystals are constructed from intermolecular interactions such as 
van der Waals contact forces, π-π interactions, and especially hydrogen bonding. There are several 
methods to obtain cocrystals in the literature, such as slow solvent evaporation, slurry crystallization, solid 
state grinding, and melting [8-13]. 
The API selected in this study is ciprofloxacin (CIP), a poorly soluble fluoroquinolone antibiotic active 
against both Gram-positive and Gram-negative bacteria, which is mainly used in the treatment of lower 
respiratory and urinary tract infections. The aim of this study is to compare the dissolution rate of CIP in 
different media and pH values to that of the prepared cocrystal with resorcinol. In addition, possible 
changes in the solid state of the drug and its cocrystal during the dissolution process are also investigated. 
Materials and methods 
Instruments 
Dissolution rate assays were carried out using a GLpKa titrator from Sirius Analytical Instruments Ltd 
(Forest Row, UK), equipped with a Sirius D-PAS spectrometer, a bifurcated fibre-optic dip probe from 
Hellma Analytics (Müllheim, Germany) with path length of 1 cm, and a two channels solvent degasser from 
SMI-LabHut Ltd. (Churcham, UK). The apparatus was controlled from a computer running the 
RefinementPro2 software. Acidity constant determinations were done with the same instrument as 
described elsewhere [14]. 
The powder X-ray diffraction (PXRD) characterization was performed using a PANalytical X’Pert PRO 
MPD / powder diffractometer of 240 mm radius equipped with a PIXcel detector from PANalytical B.V. 
(Almelo, The Netherlands). The apparatus was set in a configuration of convergent beam with a focalizing 
mirror and a transmission geometry, with flat samples sandwiched between low absorbing films. The 
detector active length was 3.347º. Work power was 45 kV – 40 mA with a defined beam height of 0.4 mm. 
Five repeated scans were done from 2 to 60 2º with a step size of 0.026 2º and a measuring time of 40 
seconds per step. 
Calorimetric analysis of the samples was performed on differential scanning calorimetry (DSC) (Mettler 
Toledo DSC822e, Switzerland). Samples equivalent to 2-5 mg of the drug or cocrystal were loaded into 
aluminum crucibles. The thermal behavior of each sample was investigated in a temperature range of 30-
300 °C with 10 °C/min heating rate under a continuous flow of dry nitrogen at 50 mL/min.     
Reagents 
Ciprofloxacin (>98 %), resorcinol (>99 %), toluene (99.9 %), and potassium chloride (>99 %) were from 
Sigma-Aldrich (St. Louis, MO, USA). Sodium acetate anhydrous (>99 %), potassium dihydrogen phosphate 
(>99.5 %), and 0.5 M NaOH standard solution (Titrisol®) were for Merck (Darmstad, Germany). FaSSIF 
(Fasted State Simulated Intestinal Fluid) and FeSSIF (Fed State Simulated Intestinal Fluid) powders were 
from Biorelevant.com (London, UK). The simulated gastrointestinal solutions of FaSSIF and FeSSIF were 
prepared as specified by the manufacturer. Water was purified by a Milli-Q plus system from Millipore 
(Bedford, MA, USA) with resistivity of 18.2MΩ cm. 
 
Methods 
Ciprofloxacin cocrystal was prepared using slurry crystallization method. 100 mg of ciprofloxacin was 
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mixed with 42 mg of resorcinol in 2 mL of toluene. The suspension was kept under stirring overnight and 
solid was collected next day by filtration under vacuum for 30 min. Then, it was characterized by DSC and 
powder X-ray diffraction (PXRD) (Figure 1). It can be observed that the signals corresponding to the 
cocrystal are different than the ones of the pure components. The formed cocrystal had 1:1 stoichiometry. 
 
Figure 1: (a) DSC curve for resorcinol, the cocrystal, and CIP. (b) PXRD diffractogram for resorcinol, the 
cocrystal, and CIP. 
For dissolution rate measurements the “GI dissolution method” has been followed [15]. Briefly, disks of 
3 mm diameter containing 8-10 mg of drug or cocrystal (8 mg of cocrystal containing around 5 mg of CIP, 
according to a 1:1 stoichiometry) were prepared by applying a constant pressure of 0.1 ton. A Sirius GLpKa 
system was used to perform the measurements. Temperature was 25±1 °C and ionic strength was kept 
constant at 0.15 M. Study was performed at different pH sectors (2.0, 4.0, 5.5, and 7.4) which are typically 
encountered in the GI tract. To perform experiments 1.5 mL of a 0.125 M acetate and 0.125 M phosphate 
buffer solution at pH = 1.6 was introduced into the sample vial. Then, the instrument added 13.5 mL of 
0.15 M aqueous KCl solution, which raised initial pH around 2. Dissolution started and the medium was 
stirred at a constant rate throughout the experiment. After 30 minutes, 0.5 M KOH solution was 
automatically dispensed to adjust to the next pH, and so on. In all experiments UV-vis spectra were 
recorded at fixed intervals, normally 30 s. Dissolution rate was determined individually at each pH sector, 
and then experiments were repeated in a full sequence of pHs (from 2.0 to 7.4) staying 30 minutes at each 
pH.  Additionally, dissolution rates were also determined in the acetate/phosphate buffer at pH 5.0 and 
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6.5, and in 15 mL of two simulated gastrointestinal fluids (FeSSIF, pH 5.0 and FaSSIF, pH 6.5). The 
concentration of sample in solution at each time point is determined from the spectroscopic data in the 
320-410 nm wavelength range, using previously determined molar extinction coefficients. In this range 
solutions of FaSSIF, FeSSIF and resorcinol present a minimum absorbance so that they don’t interfere in the 
quantification of ciprofloxacin. Data corresponding to saturated signals were excluded for the calculation. 
Equation 1 was used to calculate the dissolution rate of the compounds, 
 
- ( - )0dX = 1-e
K t t
St
 
 
 
 (1) 
where [X]t is the weight (in grams) of the compound in solution at time t (min), S is the extrapolated 
solubility (g) of the drug, Kd is the rate constant for dissolution (min
-1
), and t0 is a term allowing for a 
temporal offset. The dissolution rate (g min
-1
) is given by the product Kd·S. 
After the dissolution rate experiments, the solid state of the remaining disks was analysed using PXRD. 
Results and Discussion 
Dissolution behaviour of ionisable compounds is strongly dependent on pH value of the surrounding 
medium. As drug moves throughout the gastrointestinal tract (GIT) it is exposed to different pH 
environments that affect its degree of ionization, solubility, and thus dissolution or precipitation, according 
to the drug ionization constants. CIP is a zwitterionic compound with pKa1 = 6.20±0.04 and pKa2 = 8.56±0.06 
(values provided at 25 °C and 0.15 M ionic strength) [16]. However, CIP exists in four different microspecies 
(X
-
, XH
±
, XH
0
, and XH2
+
) in solution. Völgyi et al. [17] studied the acid base equilibria of CIP and determined 
its protonation macroconstants and microconstants. Figure 2 shows the species distribution curve of this 
compound according to the values provided in the study. The zwitterionic species is always predominant 
relative to the non-charged species independently of the pH of the solution. CIP is positively charged at low 
pH values, and its ionization degree decreases as pH increases. The maximum percentage of zwitterionic 
form and neutral forms exist at pH 7.3, where CIP has a log S0 around -3.7 (-3.62 [18], -3.72 [19], and -3.76 
measured in this work by the shake-flask method according to [20]). At higher pH values, ionization degree 
rises again due to the deprotonation of the basic group. On the contrary, resorcinol is a highly soluble very 
weak diacid which remains non‐ionized (neutral) in the whole pH range between 2 and 7.4. 
Figure 3 shows the aqueous dissolution profile at separate pH sectors for ciprofloxacin and its cocrystal 
with resorcinol (CIP-R). The dissolution rate reached a maximum value at pH 2, where both CIP and CIP-R 
totally dissolve. As pH of the medium increases, the percentage of CIP dissolved and its dissolution rate 
start to decrease, as stated in Table 1.  
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Figure 2: species distribution diagram for CIP, according to the acidity macroconstant and 
microconstantvalues provided in [17]. 
Table 1: Percentage of CIP dissolved, and dissolution rate of CIP and CIP-R in the dissolution 
experiments at different pH sectors. 
pH % CIP Dissolved  Dissolution Rate (mg/min) 
 Ciprofloxacin Cocrystal  Ciprofloxacin Cocrystal 
2.01 ± 0.04 97.5 ± 0.1 100.0 ± 0.3  1.2 ± 0.2 0.56 ± 0.06 
4.01 ± 0.05 41 ± 3 98.0 ± 0.5   0.13 ± 0.01 0.23 ± 0.9 
5.41 ± 0.03 7.1 ± 0.7 11 ± 1  0.017 ± 0.006 0.021 ± 0.001 
7.41 ± 0.08 3.7 ± 0.2 6 ± 1  0.0033 ± 0.0004 0.003 ± 0.002 
This is the expected behavior according to the ionization state of CIP. The percentage of dissolved CIP 
decreases dramatically when changing pH from 2 to 4, with only 41% dissolved after 30 minutes (Table 1), 
and drops to around 6 and 4% at pH 5.5 and 7.4, respectively. Instead, the cocrystal dissolves totally after 
25 minutes at pH 4, but its dissolution also decreases significantly at pH 5.5 and 7.4 (11 and 6% of CIP 
dissolved) respectively. Dissolution rate is directly related to the slope of the dissolution curve. Comparison 
of dissolution rates between CIP and its CIP-R evidences that at very low pH values (pH 2) the dissolution 
rate of CIP is more than twice the one of the cocrystal, probably due to the effect of resorcinol (neutral at 
this pH), which slows dissolution of CIP-R down. However, as pH increases the dissolution rate of CIP and 
CIP-R tend to be the same, reaching a minimum value of 0.003 mg min-1 at pH 7.4. 
On the contrary, the full pH experiment (Figure 4) does not reflect the actual dissolution rate of the 
compound at each pH, as both CIP and CIP-R dissolve almost totally at the first sector (pH 2). Then 
solutions stay supersaturated at the following pH sectors (4.0, 5.5, and 7.4). In case of CIP there is evidence 
of precipitation at pH 7.4, since the signal falls to zero. Although this kind of experiment does not allow 
knowing the dissolution behavior of the compounds at a given pH because each sector is influenced by the 
previous one, it can simulate better the processes that compounds experience when moving along the 
gastrointestinal tract, where different pH environments are encountered.  
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Figure 3: Dissolution profile at separate pH sectors for CIP (●) and its CIP-R (○): (a) pH = 2; (b) pH = 4; (c) pH = 5.5; 
(d) pH = 7.4. 
X-ray analysis of the surface of the solid remaining in the disks indicates that approximately 50% of the 
solid remaining in CIP tablets is transformed to CIP·3H2O, whatever the working pH. Meanwhile, the 
surface of the cocrystal tablets contain about 90% of the original cocrystal, and only 10% of CIP·3H2O. 
These transformations in the tablet surface may modify, to some extent, the dissolution of the compounds, 
especially for CIP where the percentage of transformation to the trihydrated form is higher. In general, the 
appearance of hydrated forms slows the dissolution process down because of the lower ion-dipole 
interaction energy liberated on its dissolution [21]. Only at pH 4.0 a slightly decrease in the dissolution rate 
of CIP compared to CIP-R was observed. Nevertheless, there are not enough evidences to know the 
reasons behind CIP-R higher dissolution rate. On one hand the cocrystal itself could dissolve faster than the 
pure API, and on the other hand there could be a decrease in the dissolution of the API caused by the 
transformation into CIP·3H2O on the surface of the tablet.  
Results of dissolution rate determinations in simulated gastrointestinal media are shown in Table 2 and 
Figure 5. Experiments have been done not only in the two gastrointestinal fluids, but also in 
acetate/phosphate buffer at the same pH. In this way it is possible to evaluate the real effect of the gastric 
media components (mainly bile salts and lecithin) to dissolution behavior of the compounds, 
independently of pH. Table 2 and Figure 5a show a different behavior of CIP and CIP-R at pH 5. The 
cocrystal dissolves faster than the pure API. However the differences cannot be attributed to FeSSIF 
components since in both cases dissolution rates are practically the same in FeSSIF and in the plain buffer.  
Again, the reason can be due to a faster dissolution of the cocrystal, or due to the transformation of the 
API into the trihydrated form, as stated by PXRD. In fact, X-ray analysis of the remaining tablets indicated 
that the surface of the cocrystals were hardly modified (90% cocrystal and 10% CIP·3H2O) in these two 
media, whereas the tables of CIP alone were strongly modified (10% CIP and 90% CIP·3H2O). As expected, 
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dissolution rate values of CIP and CIP-R at pH 5 are in between the ones determined at pH 4.0 and 5.5 
(Table 1).  
 
Figure 4: Full pH dissolution experiment for CIP (●) and CIP-R (○). 
 
Results in FaSSIF and the corresponding plain buffer (pH 6.4) (Figure 3b) show that either dissolution 
rate or percentage of CIP dissolved for CIP and CIP-R are equivalent. Again, these results are located in 
between the results at pH 5.5 and 7.4 in Table 1 for both compounds. Thus, apparently there is no effect of 
FaSSIF or FeSSIF components on the dissolution rate; only the ionization degree seems to play an 
important role in their dissolution. The zwitterionic nature of CIP may be one of the reasons that 
gastrointestinal simulated fluids have no solubilizing effect on CIP, since other studies [22-24] point out 
that the micelles formed in these fluids have negatively charged surface, what means attraction for 
cations, repulsion for anions, and may be no effect on zwitterions. 
Table 2: Percentage of CIP dissolved, and dissolution rate of CIP and CIP-R; in FeSSIF, FaSSIF and in standard 
buffer at the same pH (5.0 and 6.5 respectively). 
pH % CIP Dissolved  Dissolution Rate (mg/min) 
 Ciprofloxacin Cocrystal  Ciprofloxacin Cocrystal 
FeSSIF (pH = 4.94 ± 0.05) 23 ± 4 94 ± 2  0.07 ± 0.01 0.25 ± 0.04 
Buffer pH = 4.94 ± 0.05 26 ± 1 105 ± 4  0.067 ± 0.001  0.29 ± 0.1 
FaSSIF (pH = 6.37 ± 0.05)  1.7 ± 0.1 2.5 ± 0.5  0.0038± 0.0004 0.005 ± 0.002 
Buffer pH = 6.43 ± 0.04 2.2 ± 0.2 2.10 ± 0.07  0.005 ± 0.001 0.003 ± 0.001 
Conclusions 
Dissolution rate of ciprofloxacin and its cocrystal with resorcinol have been determined at several pH 
values of pharmaceutical interest in an acetate-phosphate buffer. Results show that dissolution rate of 
ciprofloxacin decreases according to ionization state of ciprofloxacin, i.e., it is maximum at pH 2 and has 
the minimum value at pH 7.4, where ciprofloxacin is mainly in its zwitterionic form. The same behavior is 
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observed with the cocrystal. However, ciprofloxacin dissolves faster than the cocrystal at pH 2, but the 
cocrystal dissolves faster than ciprofloxacin at intermediate pH values (4.0, 5.0 and 5.5). The reason can be 
attributed either to a better dissolution of the cocrystal itself, or a decrease in the dissolution of 
ciprofloxacin due to the formation of the more insoluble trihydrated form in the surface of the tablets, as 
stated by PXRD. Gastric fluid components such as lecithin and bile salts have not shown any improvement 
in the dissolution rate of the studied compounds. 
 
Figure 5: Dissolution profile in simulated gastrointestinal fluids and buffer at the same pH. (a) CIP in FeSSIF 
(●), CIP in buffer at pH 5 (▲), CIP-R in FeSSIF (○), CIP-R in buffer at pH 5 (∆); (b) CIP in FaSSIF (●), CIP in buffer 
at pH 6.5 (▲), CIP-R in FaSSIF (○), CIP-R in buffer at pH 6.5 (∆). 
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